NEW YORK (GenomeWeb) – PrimBio Research Institute has tapped Tute Genomics to be its primary provider of whole-exome and targeted gene panel interpretation services.
PrimBio is a certified Life Technologies Ampliseq Exome sequencing provider that offers targeted exome and ampliseq exome sequencing services including library preparation, alignment, and variant calling. In addition to interpreting the fruits of its whole-exome sequencing service, PrimBio will use Tute's services for six targeted gene panel offerings: its cancer hotspot panel, comprehensive cancer panel, inherited disease panel, BRCA1 and BRCA2 panel, breast cancer panel, and colorectal cancer panel.
"Our mission is to make precision medicine a reality by enabling researchers and clinicians to utilize human genome data for scientific discovery and individualized treatment," Reid Robison, Tute Genomics' CEO, said in a statement. "Our partnership with PrimBio is an example of a fully integrated pipeline with sample to report capability, to accelerate genomics research and enable personalized medicine."
Financial and other terms of the agreement were not disclosed.